With offices in Philadelphia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion.
Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
To learn about career opportunities contact us at careers@swanbiotx.com.
Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
To learn about career opportunities contact us at careers@swanbiotx.com.
Location: United States, Pennsylvania, Lower Merion Township
Employees: 11-50
Total raised: $108M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Syncona Pa... | synconaltd... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.05.2022 | Series B | $56M | Syncona Pa... |
| 24.04.2020 | Series A | $52M | - |
Mentions in press and media 2
| Date | Title | Description |
| 19.05.2022 | SwanBio Therapeutics Raises $56 Million in Series B Financing | SwanBio Therapeutics, a Philadelphia, PA-based gene therapy company, raised $56M in Series B funding. The round, which brings total financing raised to date to $133 million, was led by Syncona Limited and Mass General Brigham Ventures. The ... |
| 24.04.2020 | SwanBio Therapeutics Raises $52M in Series A | SwanBio Therapeutics, a Bala Cynwyd, Pa.-based gene therapy company developing medicines to deliver clinical efficacy for the treatment of AMN and other neurological diseases, completed a $52m expanded Series A financing. Syncona Ltd. and P... |